Press Release Series C | 4TEEN4 Pharmaceuticals | 19 comments

Funding Rounds

▤ Summary

4TEEN4 Pharmaceuticals has closed a Series C extension that brings total funding to 55 million euros, or about $64 million. The company will use the money to advance procizumab, which is now in a Phase 2a study for patients with cardiogenic shock and elevated cDPP3 levels. It also plans to widen the study across Europe and prepare for U.S. expansion. The financing supports the company’s next clinical and operational milestones ahead of a pivotal trial.

$ Funding

$
Amount $64.0M Total raised
□
Date November 13, 2025 Announcement date
◎
Investors - Lead investors
▥
Company 4teen4.de Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies